Currently, ivosidenib is approved as a monotherapy or with azacitidine for the treatment of IDH1-mutated newly diagnosed AML in adults aged 75 years or older or those ineligible for intensive induction chemotherapy, as well as a monotherapy to treat adult patients with relapsed or refractory AML [93,94,95]. This evidence concerns the gene IDH1 and acute myeloid leukemia.